Zepbound 7.5 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26F3EX2
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $47,512
Award facts
- Contract value 100% obligated
- $47,511.51 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $47,511.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injectors on December 18, 2025, with completion targeted for December 19, 2025. This is a non-set-aside competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is AmerisourceBergen's headquarters in Conshohocken, Pennsylvania. As a child contract under the IDC, this delivery order represents a routine pharmaceutical procurement to support military and federal healthcare systems' medical supply needs.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates consistent capability in delivering a comprehensive range of pharmaceutical products, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. This award for Zepbound reflects the company's ongoing role as a primary vendor in the DLA's pharmaceutical supply chain, which is expected to evolve under the planned Pharmaceutical Prime Vendor Global Program Generation V initiative involving multiple regional contractors.
Quick answers
Who was awarded contract SPE2DR26F3EX2?
SPE2DR26F3EX2 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 18, 2025.
How much is contract SPE2DR26F3EX2 worth?
The government has obligated $47,512 on SPE2DR26F3EX2.
Is contract SPE2DR26F3EX2 an order under another contract?
Yes. SPE2DR26F3EX2 is a delivery order under SPE2DR25D3017, an indefinite delivery contract.
Was contract SPE2DR26F3EX2 competed?
The extent of competition for SPE2DR26F3EX2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award